Literature DB >> 33543866

Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.

Till Braun1, Markus Glass2, Linus Wahnschaffe3, Moritz Otte3, Petra Mayer3, Marek Franitza4, Janine Altmüller4, Michael Hallek3, Stefan Hüttelmaier2, Alexandra Schrader3, Marco Herling5.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic mature T-cell malignancy. It typically presents with exponentially rising lymphocyte counts, splenomegaly, and bone marrow infiltration. Effective treatment options are scarce and a better understanding of TPLL's pathogenesis is desirable. Activation of the TCL1 proto-oncogene and loss-of-function perturbations of the tumor suppressor ATM are TPLL's genomic hallmarks. The leukemic cell reveals a phenotype of active T-cell receptor (TCR) signaling and aberrant DNA damage responses. Regulatory networks based on the profile of microRNA (miR) have not been described for T-PLL. In a combined approach of small-RNA and transcriptome sequencing in 46 clinically and moleculary well-characterized T-PLL, we identified a global T-PLL-specific miR expression profile that involves 34 significantly deregulated miR species. This pattern strikingly resembled miR-ome signatures of TCR-activated T cells. By integrating these T-PLL miR profiles with transcriptome data, we uncovered regulatory networks associated with cell survival signaling and DNA damage response pathways. Despite a miR-ome that discerned leukemic from normal T cells, there were also robust subsets of T-PLL defined by a small set of specific miR. Most prominently, miR-141 and the miR- 200c-cluster separated cases into two major subgroups. Furthermore, increased expression of miR-223-3p as well as reduced expression of miR-21 and the miR-29 cluster were associated with more activated Tcell phenotypes and more aggressive disease presentations. Based on the implicated pathobiological role of these miR deregulations, targeting strategies around their effectors appear worth pursuing. We also established a combinatorial miR-based overall survival score for T-PLL (miROS-T-PLL), that might improve current clinical stratifications.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33543866      PMCID: PMC8719084          DOI: 10.3324/haematol.2020.267500

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  49 in total

1.  Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.

Authors:  Rebecca Kohnken; Jing Wen; Bethany Mundy-Bosse; Kathleen McConnell; Ashleigh Keiter; Leah Grinshpun; Alex Hartlage; Max Yano; Betina McNeil; Nitin Chakravarti; Basem William; James E Bradner; Michael A Caligiuri; Pierluigi Porcu; Anjali Mishra
Journal:  Blood       Date:  2017-11-27       Impact factor: 22.113

2.  Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.

Authors:  Claire E Dearden; Amit Khot; Monica Else; Mike Hamblin; Effie Grand; Ashok Roy; Saman Hewamana; Estella Matutes; Daniel Catovsky
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

3.  MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma.

Authors:  Xiaoyan Shen; Bo Wang; Kejia Li; Lili Wang; Xiaoqing Zhao; Feng Xue; Ruofei Shi; Jie Zheng
Journal:  J Invest Dermatol       Date:  2018-03-17       Impact factor: 8.551

4.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

5.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

6.  First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Authors:  Bernd Boidol; Christoph Kornauth; Emiel van der Kouwe; Nicole Prutsch; Lukas Kazianka; Sinan Gültekin; Gregor Hoermann; Marius E Mayerhoefer; Georg Hopfinger; Alexander Hauswirth; Michael Panny; Marie-Bernadette Aretin; Bernadette Hilgarth; Wolfgang R Sperr; Peter Valent; Ingrid Simonitsch-Klupp; Richard Moriggl; Olaf Merkel; Lukas Kenner; Ulrich Jäger; Stefan Kubicek; Philipp B Staber
Journal:  Blood       Date:  2017-09-27       Impact factor: 22.113

7.  Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray.

Authors:  Jie Li; Yi Qin; Haiyan Zhang
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

8.  Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing.

Authors:  Annelynn Wallaert; Wouter Van Loocke; Lucie Hernandez; Tom Taghon; Frank Speleman; Pieter Van Vlierberghe
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

9.  MicroRNA expression profiles in human CD3+ T cells following stimulation with anti-human CD3 antibodies.

Authors:  Isabel Garcia Sousa; Manuela Maragno do Almo; Kelly Cristina Rodrigues Simi; Maryani Andressa Gomes Bezerra; Rosângela Vieira Andrade; Andréa Queiroz Maranhão; Marcelo Macedo Brigido
Journal:  BMC Res Notes       Date:  2017-03-14

Review 10.  Argonaute 2: A Novel Rising Star in Cancer Research.

Authors:  ZhenLong Ye; HuaJun Jin; QiJun Qian
Journal:  J Cancer       Date:  2015-07-16       Impact factor: 4.207

View more
  1 in total

1.  Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.

Authors:  Nathan Mikhaylenko; Linus Wahnschaffe; Marco Herling; Ingo Roeder; Michael Seifert
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.